Galyna Vorokhib
Primary Care · Philadelphia, PANPI 1508403569
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by Medtronic at 25.3% of the total. Among primary care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $38.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$2K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$855
- AbbVie$755
- Corcept Therapeutics$551
- plus $4K from 34 others
What the payments were for
- Travel & lodging$1,0148%
- Food & beverage$11,24092%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 59 | $3,108 |
| Novo Nordisk | 48 | $2,037 |
| AstraZeneca | 24 | $1,251 |
| Sanofi-aventis U.S. LLC | 14 | $855 |
| AbbVie | 9 | $755 |
| Corcept Therapeutics | 16 | $551 |
| Boehringer Ingelheim | 16 | $416 |
| E.r. Squibb & Sons, L.L.C. | 4 | $396 |
| Novartis | 27 | $359 |
| Lilly USA, LLC | 18 | $347 |
| Amgen | 12 | $309 |
| Aimmune Therapeutics, Inc. | 7 | $289 |
| Xeris Pharmaceuticals, Inc. | 9 | $185 |
| Amphastar Pharmaceuticals, Inc. | 7 | $130 |
| Nestle Healthcare Nutrition Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Intuity Medical Inc | 1 | $117 |
| Kyowa Kirin, Inc. | 3 | $77 |
| Dexcom, Inc. | 3 | $73 |
| Radius Health, Inc. | 3 | $71 |
| Tandem Diabetes Care, Inc. | 2 | $58 |
| BETA Bionics, Inc. | 2 | $54 |
| Bayer | 3 | $50 |
| Averitas Pharma Inc. | 2 | $47 |
| Insulet Corporation | 2 | $47 |
| Pfizer | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| BD | 2 | $45 |
| Mannkind Corporation | 2 | $43 |
| Amarin Pharma, Inc. | 3 | $42 |
| Harmony Biosciences LLC | 1 | $37 |
| Ascensia Diabetes Care US Inc. | 1 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Intra-sana Laboratories | 1 | $23 |
| Almatica Pharma LLC | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Merck | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,728
- FARXIGA$999
- RYBELSUS$720
- UBRELVY$597
- Ozempic$460
- ZENPEP$375
- QULIPTA$353
- SOLIQUA 100/33$339
- TOUJEO$269
- CAMZYOS$260
- Korlym$232
- Minimed 630G$161
- JARDIANCE$125
- Repatha$125
- ELIQUIS$125
- NEXLIZET$125
- NEXLETOL$125
- Wegovy$125
- Pogo Automatic Blood Glucose Monitoring System$117
- INPEN SMART INSULIN DELIVERY SYSTEM$101
How this compares
$12,272 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 669 | $713,843 |
| OzempicSemaglutide | 280 | $281,416 |
| JardianceEmpagliflozin | 318 | $255,550 |
| FarxigaDapagliflozin Propanediol | 158 | $133,528 |
| JanuviaSitagliptin Phosphate | 117 | $86,952 |
| RybelsusSemaglutide | 54 | $67,930 |
| MounjaroTirzepatide | 53 | $59,098 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $52,685 |
| TradjentaLinagliptin | 76 | $51,147 |
| Novolog FlexpenInsulin Aspart | 189 | $43,419 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $43,084 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 417 | $42,989 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 28 | $40,167 |
| Humalog Kwikpen U-100Insulin Lispro | 181 | $34,485 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 134 | $26,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $347 | $776,193734 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $2,037 | $354,644349 claims |
| Boehringer IngelheimJardiance, Tradjenta | $416 | $306,697394 claims |
| AstraZenecaFarxiga | $1,251 | $133,528158 claims |
| MerckJanuvia | $14 | $86,952117 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $855 | $10,09012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Philadelphia
- Teresa GiamboyPhiladelphia$21K
- Kaylee BakerPhiladelphia$7K
- Jarrell HillPhiladelphia$6K
- Valerie DailyPhiladelphia$4K
- Adunni WardPhiladelphia$3K
- Avigad FeldmanPhiladelphia$3K
- Peggy DerussoPhiladelphia$3K
- Jennifer MalloyPhiladelphia$3K
- Emily MateyPhiladelphia$2K
- Kersten ReiderMount Penn$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.